Literature DB >> 26192152

Clinical Outcomes Associated with Thermal Pulsation System Treatment.

Pam Satjawatcharaphong1, Shaokui Ge, Meng C Lin.   

Abstract

PURPOSE: To identify patient characteristics at a baseline ocular surface evaluation that correlate with improvement in dry eye symptoms at a follow-up visit after treatment with the LipiFlow Thermal Pulsation System.
METHODS: Thirty-two patients completed a comprehensive baseline ocular surface evaluation and were treated with the LipiFlow Thermal Pulsation System followed by maintenance home therapy. Lipid layer thickness and blink pattern were determined using the LipiView Interferometer. Noninvasive tear breakup time was measured using a Medmont E300 Corneal Topographer. Slit lamp biomicroscopy was used to evaluate invasive tear breakup time and corneal staining after instillation of fluorescein dye. Conjunctival staining, location of the line of Marx, and presence of lid wiper epitheliopathy were evaluated with lissamine green dye. Meibomian gland expressibility was scored using the TearScience Meibomian Gland Evaluator, and meibography was imaged using the Oculus Keratograph. A logistic regression model was used to estimate the odds ratios for having a decreased posttreatment score (reduced symptoms) of Standard Patient Evaluation of Eye Dryness (SPEED).
RESULTS: Baseline SPEED score (p = 0.01) and sex (p = 0.03) had significant odds ratios at the α = 0.05 level. Baseline noninvasive tear breakup time (p = 0.07), number of grade 0 meibomian glands in the lower lid (p = 0.09), and conjunctival staining grade in the inferior region (p = 0.10) met an α = 0.10 criterion for significant odds ratios, but not the typical α = 0.05 criterion. Higher baseline SPEED score and male sex had greater odds for decreased posttreatment SPEED score.
CONCLUSIONS: Our results identified factors that better select candidates for LipiFlow Thermal Pulsation System.

Entities:  

Mesh:

Year:  2015        PMID: 26192152     DOI: 10.1097/OPX.0000000000000670

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  11 in total

1.  Impact of Improper Approach to Identify Lid Wiper Epitheliopathy (LWE).

Authors:  Christopher W Lievens; Yvonne Norgett; Nancy Briggs; Peter M Allen; Marta Vianya-Estopa
Journal:  Clin Ophthalmol       Date:  2020-10-06

2.  Thermal Pulsation with or without Dexamethasone Intracanalicular Insert for Meibomian Gland Dysfunction: A Prospective, Masked Trial.

Authors:  Damon S Dierker; Scott G Hauswirth
Journal:  Clin Ophthalmol       Date:  2022-05-12

3.  Meibomian Gland Contrast Sensitivity and Specificity in the Diagnosis of Lipid-deficient Dry Eye: A Pilot Study.

Authors:  Thao N Yeh; Meng C Lin
Journal:  Optom Vis Sci       Date:  2021-02-01       Impact factor: 2.106

4.  Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.

Authors:  Ren-Wen Ho; Po-Chiung Fang; Tsai-Ling Chao; Chun-Chih Chien; Ming-Tse Kuo
Journal:  Sci Rep       Date:  2018-05-30       Impact factor: 4.379

5.  Risk factors for severe Meibomian gland atrophy in a young adult population: A cross-sectional study.

Authors:  Thao N Yeh; Meng C Lin
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

6.  Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial.

Authors:  Joseph Tauber; James Owen; Marc Bloomenstein; John Hovanesian; Mark A Bullimore
Journal:  Clin Ophthalmol       Date:  2020-02-12

7.  Evaluation of tear film and the morphological changes of meibomian glands in young Asian soft contact lens wearers and non-wearers.

Authors:  Tianpu Gu; Lu Zhao; Zhuzhu Liu; Shaozhen Zhao; Hong Nian; Ruihua Wei
Journal:  BMC Ophthalmol       Date:  2020-03-04       Impact factor: 2.209

Review 8.  Eyelid Warming Devices: Safety, Efficacy, and Place in Therapy.

Authors:  Brandon Bzovey; William Ngo
Journal:  Clin Optom (Auckl)       Date:  2022-08-05

9.  The function and morphology of Meibomian glands in patients with thyroid eye disease: a preliminary study.

Authors:  Chia-Yu Wang; Ren-Wen Ho; Po-Chiung Fang; Hun-Ju Yu; Chun-Chih Chien; Chang-Chun Hsiao; Ming-Tse Kuo
Journal:  BMC Ophthalmol       Date:  2018-04-12       Impact factor: 2.209

Review 10.  Non-pharmaceutical treatment options for meibomian gland dysfunction.

Authors:  Reiko Arita; Shima Fukuoka
Journal:  Clin Exp Optom       Date:  2020-01-13       Impact factor: 2.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.